Rossari Biotech Limited is a prominent India-based specialty chemicals manufacturer. Established in 2003, the company has grown to become one of India's largest manufacturers of textile specialty chemicals and a leading provider of over 4,280 products across three key verticals. Its offerings cater to global brands in the FMCG sector and are utilized in a wide array of consumer-centric products, including home and personal care items, textile chemicals, and animal health and nutrition products. Rossari Biotech serves customers worldwide, positioning itself as a significant player in the global specialty chemicals industry.
The company operates through three distinct segments:
This segment focuses on manufacturing chemicals for the consumer goods industry. HPPC produces acrylic polymers and offers a sustainable range of products for various cleaning industry applications. The company's portfolio includes chemicals for personal care, soaps, detergents, paints and coatings, and water treatment.
Representing the company's core strength, the TSC segment is dedicated to providing eco-friendly and sustainable chemical solutions for the textile industry. It offers solutions for pre-treatment, dyeing, printing, finishing, and specialized chemicals across the entire textile value chain, including cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printing, and sustainable solutions.
The AHN segment caters to the animal health and nutrition market. This includes poultry nutrition products such as vitamin-mineral formulations, toxin binders, individual and cocktail enzymes, liquid nutraceuticals, and supplements or herbal preparations. Additionally, the company provides pet grooming products, including natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquids, under brand names like Lozalo, Hunger Fills, and Sniffy.
Rossari Biotech maintains a strong focus on innovation with two R&D facilities: one at its Silvassa manufacturing facility and a dedicated research lab at IIT Bombay. This dual approach ensures continuous product development and maintains the company's competitive edge in the market.
For the full year ended March 2025, Rossari Biotech reported a net profit of ₹136.38 crore, a 4.35% increase from ₹130.69 crore in the previous fiscal year. Revenue for the same period rose by 13.64% to ₹2,080.29 crore, up from ₹1,830.56 crore in the prior year.
In the quarter ended March 2025, net profit increased by 0.91% to ₹34.44 crore, compared to ₹34.13 crore in the same quarter of the previous year. Revenue for the quarter grew by 22.60% to ₹579.56 crore, from ₹472.72 crore in the corresponding quarter of the previous year.
The company demonstrated robust performance in Q1 FY2025, with revenue growing 19.3% year-over-year to ₹489.7 crore. EBITDA saw a 12.5% YoY increase to ₹64.9 crore, indicating healthy profitability. Profit After Tax (PAT) rose by 19.5% YoY to ₹34.9 crore, reflecting effective cost management.
- Revenue (Q1 FY25): ₹579.56 Crore
- Net Profit (Q1 FY25): ₹34.44 Crore
- Market Capitalization: ₹3,913 Crore
- Return on Equity (Last 3 Years): 12.6%
The company declared a dividend of Re. 0.50 per share for FY 2024-25. The board has approved a final dividend of Rs 0.50 per share for the financial year ended March 31, 2025. The dividend payout has been conservative, representing 2.24% of profits over the last 3 years.
Rossari Biotech has approved capacity expansions for its subsidiaries, Unitop Chemicals and Tristar Intermediates, with a total investment of ₹97 crore. The company is also investing an additional ₹95 crore at Rossari Biotech for capacity enhancement. These strategic moves are designed to bolster production capabilities and align with market demand forecasts.
The company's expansion plans to add High Performance Personal Care (HPPC) and Ethoxylation capacities are progressing on schedule and are expected to be commissioned in phases during the current year, poised to drive future growth.
Rossari Biotech is targeting a revenue growth of 10–15% in FY26, with a strategic focus on expanding exports and increasing production capacity. The company maintains a strong financial position characterized by low net debt. Its growth strategy emphasizes broadening its customer base, expanding its geographical reach, and prioritizing higher-margin products.
The company remains committed to delivering sustainable, profitable growth through sharp execution, customer-centric innovation, and strategic diversification. Supported by a strong balance sheet, an agile business model, and a growing global footprint, Rossari Biotech is confident in its ability to maintain healthy growth momentum in the coming years.
